182 related articles for article (PubMed ID: 32890517)
1. Breast, Prostate, and Rectal Cancer: Should 5-5-5 Be a New Standard of Care?
Ling DC; Vargo JA; Beriwal S
Int J Radiat Oncol Biol Phys; 2020 Oct; 108(2):390-393. PubMed ID: 32890517
[No Abstract] [Full Text] [Related]
2. Assessment of Simulated SARS-CoV-2 Infection and Mortality Risk Associated With Radiation Therapy Among Patients in 8 Randomized Clinical Trials.
Tabrizi S; Trippa L; Cagney D; Aizer AA; Tanguturi S; Ventz S; Fell G; Bellon JR; Mamon H; Nguyen PL; D'Amico AV; Haas-Kogan D; Alexander BM; Rahman R
JAMA Netw Open; 2021 Mar; 4(3):e213304. PubMed ID: 33779742
[TBL] [Abstract][Full Text] [Related]
3. Ultrahypofractionation Should be a Standard of Care Option for Intermediate-Risk Prostate Cancer.
Loblaw A
Clin Oncol (R Coll Radiol); 2020 Mar; 32(3):170-174. PubMed ID: 31787501
[No Abstract] [Full Text] [Related]
4. Are We Now Able to Define Guidelines for Moderate Hypofractionation in Prostate Cancer Radiation Therapy?
Brenner DJ; Hall EJ
Int J Radiat Oncol Biol Phys; 2018 Mar; 100(4):871-873. PubMed ID: 29485065
[No Abstract] [Full Text] [Related]
5. Moderate hypofractionation and stereotactic body radiation therapy in the treatment of prostate cancer.
Beckta JM; Nosrati JD; Yu JB
Urol Oncol; 2019 Sep; 37(9):619-627. PubMed ID: 30738746
[TBL] [Abstract][Full Text] [Related]
6. Rationale for hypofractionation.
Hennequin C; Guillerm S; Quero L
Cancer Radiother; 2019 Oct; 23(6-7):500-502. PubMed ID: 31444076
[TBL] [Abstract][Full Text] [Related]
7. Is moderate hypofractionation accepted as a new standard of care in north america for prostate cancer patients treated with external beam radiotherapy? Survey of genitourinary expert radiation oncologists.
McClelland S; Sandler KA; Degnin C; Chen Y; Hung AY; Mitin TE
Int Braz J Urol; 2019; 45(2):273-287. PubMed ID: 30676300
[TBL] [Abstract][Full Text] [Related]
8. PROshot: Internal Mammary Coverage, Dose-Reduced Radiation After Transoral Surgery, Sequencing of Total Neoadjuvant Therapy for Rectal Cancer, Hypofractionated Whole Breast Intensity Modulated Radiation Therapy, Hypofractionated Prostate Fossa Radiation Therapy, and Stereotactic Body Radiation Therapy for Oligoprogressive Cancer.
Dulaney C; Dover L
Pract Radiat Oncol; 2022; 12(2):79-83. PubMed ID: 35248240
[No Abstract] [Full Text] [Related]
9. [25th meeting of the European Society for Therapeutic Radiology and Oncology (ESTRO)].
Mazeron JJ
Bull Cancer; 2006 Dec; 93(12):1241-4. PubMed ID: 17182379
[No Abstract] [Full Text] [Related]
10. Important Technical Considerations for Implementing the ASTRO/ASCO/AUA Prostate Cancer Hypofractionated Radiation Guideline.
LaRiviere MJ; Zhu TC; Christodouleas JP
Pract Radiat Oncol; 2019; 9(4):197-199. PubMed ID: 30836189
[No Abstract] [Full Text] [Related]
11. SBRT for Localized Prostate Cancer: Is it Ready for Take-Off?
Mitin T; Henry A; Choudhury A; Chen RC; Pinkawa M; Spratt DE
Int J Radiat Oncol Biol Phys; 2019 Nov; 105(3):618-620. PubMed ID: 31540596
[No Abstract] [Full Text] [Related]
12. COVID-19 and radiotherapy: potential new strategies for patients management with hypofractionation and telemedicine.
Di Franco R; Borzillo V; D'Ippolito E; Scipilliti E; Petito A; Facchini G; Berretta M; Muto P
Eur Rev Med Pharmacol Sci; 2020 Dec; 24(23):12480-12489. PubMed ID: 33336767
[TBL] [Abstract][Full Text] [Related]
13. [Minutes of the 23th meeting of the European Society for Therapeutic Radiology and Oncology (ESTRO). Amsterdam, 24-28 October 2004].
Mazeron JJ;
Cancer Radiother; 2005 Mar; 9(2):122-6. PubMed ID: 15820439
[No Abstract] [Full Text] [Related]
14. [Trends in the use of primary radiotherapy for cancer in the Netherlands in patients with breast, prostate, rectal and lung tumours].
Struikmans H; Aarts MJ; Jobsen JJ; Koning CC; Poortmans PM; Louwman MW; Coebergh JW
Ned Tijdschr Geneeskd; 2012; 156(12):A4426. PubMed ID: 22436526
[TBL] [Abstract][Full Text] [Related]
15. [Concurrent chemoradiotherapy update].
Reboul F; Vincent P; Chauvet B; Alfonsi M; Berger C; Serin D
Bull Cancer; 1999 Jan; 86(1):77-83. PubMed ID: 10029709
[No Abstract] [Full Text] [Related]
16. Hypofractionation for clinically localized prostate cancer.
Hickey BE; James ML; Daly T; Soh FY; Jeffery M
Cochrane Database Syst Rev; 2019 Sep; 9(9):CD011462. PubMed ID: 31476800
[TBL] [Abstract][Full Text] [Related]
17. Elective Pelvic Nodal Irradiation With a Simultaneous Hypofractionated Integrated Prostate Boost for Localised Prostate Cancer: Ready for Prime Time?
Cheung P; Niazi T; Faria S; Loblaw A
Clin Oncol (R Coll Radiol); 2020 Mar; 32(3):181-188. PubMed ID: 31926820
[TBL] [Abstract][Full Text] [Related]
18. [Moderate or extreme hypofractionation and localized prostate cancer: The times are changing].
Line Krhili S; Créhange G; Albert-Dufrois H; Guimas V; Minsat M; Supiot S
Cancer Radiother; 2019 Oct; 23(6-7):503-509. PubMed ID: 31471253
[TBL] [Abstract][Full Text] [Related]
19. Assessment of non-inferiority with meta-analysis: example of hypofractionated radiation therapy in breast and prostate cancer.
Trone JC; Ollier E; Chapelle C; Mismetti P; Cucherat M; Magné N; Zuffrey PJ; Laporte S
Sci Rep; 2020 Sep; 10(1):15415. PubMed ID: 32963332
[TBL] [Abstract][Full Text] [Related]
20. [Reappraisal role of locoregional radiation therapy in metastatic cancers].
Rancoule C; Pacaut-Vassal C; Vallard A; Mery B; Trone JC; El Meddeb Hamrouni A; Magné N
Bull Cancer; 2017 Jan; 104(1):86-91. PubMed ID: 27955816
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
